$MTEM
Molecular Templates, Inc.

2012 Q4 Form 10-Q Financial Statement

#000119312512449282 Filed on November 02, 2012

View on sec.gov

Income Statement

Concept 2012 Q4 2012 Q3 2011 Q3
Revenue $2.020M $1.800M $0.00
YoY Change 3266.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.850M $1.740M $1.310M
YoY Change 30.28% 32.82% 0.77%
% of Gross Profit
Research & Development $6.160M $4.039M $6.481M
YoY Change -8.61% -37.68% 35.87%
% of Gross Profit
Depreciation & Amortization $340.0K $340.0K $160.0K
YoY Change 161.54% 112.5% 23.08%
% of Gross Profit
Operating Expenses $8.010M $5.780M $7.789M
YoY Change -1.84% -25.79% 28.32%
Operating Profit -$3.983M -$7.789M
YoY Change -48.86%
Interest Expense $30.00K $25.00K $10.00K
YoY Change 200.0% 150.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $34.36M $2.970M $3.660M
YoY Change 1118.44% -18.85% 2340.0%
Pretax Income $28.39M -$991.0K -$4.130M
YoY Change -637.69% -76.0% -30.12%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings $28.39M -$991.0K -$4.125M
YoY Change -638.16% -75.98% -30.2%
Net Earnings / Revenue 1405.35% -55.06%
Basic Earnings Per Share $0.50 -$0.02 -$0.08
Diluted Earnings Per Share -$0.10 -$0.06 -$0.08
COMMON SHARES
Basic Shares Outstanding 56.25M shares 55.65M shares 49.05M shares
Diluted Shares Outstanding 64.41M shares 49.05M shares

Balance Sheet

Concept 2012 Q4 2012 Q3 2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $70.80M $65.80M $25.30M
YoY Change 248.77% 160.08% 25.87%
Cash & Equivalents $11.03M $8.634M $6.076M
Short-Term Investments $59.80M $57.20M $19.20M
Other Short-Term Assets $1.200M $1.100M $800.0K
YoY Change 300.0% 37.5% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $87.65M $84.43M $26.10M
YoY Change 326.65% 223.49% 25.48%
LONG-TERM ASSETS
Property, Plant & Equipment $812.0K $728.0K $400.0K
YoY Change 49.54% 82.0% 33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.059M $1.059M $300.0K
YoY Change -21.5% 253.0% -62.5%
Total Long-Term Assets $1.871M $1.787M $800.0K
YoY Change -1.11% 123.38% -27.27%
TOTAL ASSETS
Total Short-Term Assets $87.65M $84.43M $26.10M
Total Long-Term Assets $1.871M $1.787M $800.0K
Total Assets $89.52M $86.22M $26.90M
YoY Change 299.01% 220.51% 22.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $908.0K $739.0K $300.0K
YoY Change -61.99% 146.33% -40.0%
Accrued Expenses $2.257M $1.817M $5.100M
YoY Change 29.94% -64.37% 75.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.45M $16.19M $5.400M
YoY Change 103.13% 199.8% 63.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $85.90M $114.1M $12.00M
YoY Change 813.83% 850.83% 62.16%
Total Long-Term Liabilities $85.90M $114.1M $12.00M
YoY Change 813.83% 850.83% 62.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.45M $16.19M $5.400M
Total Long-Term Liabilities $85.90M $114.1M $12.00M
Total Liabilities $103.4M $130.3M $17.40M
YoY Change 475.8% 648.86% 62.62%
SHAREHOLDERS EQUITY
Retained Earnings -$323.3M -$351.7M
YoY Change 28.21%
Common Stock $309.4M $307.6M
YoY Change 20.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$13.85M -$44.08M $9.500M
YoY Change
Total Liabilities & Shareholders Equity $89.52M $86.22M $26.90M
YoY Change 299.01% 220.51% 22.83%

Cashflow Statement

Concept 2012 Q4 2012 Q3 2011 Q3
OPERATING ACTIVITIES
Net Income $28.39M -$991.0K -$4.125M
YoY Change -638.16% -75.98% -30.2%
Depreciation, Depletion And Amortization $340.0K $340.0K $160.0K
YoY Change 161.54% 112.5% 23.08%
Cash From Operating Activities $4.980M -$2.250M -$6.340M
YoY Change -205.06% -64.51% 4.28%
INVESTING ACTIVITIES
Capital Expenditures -$150.0K -$100.0K -$320.0K
YoY Change -28.57% -68.75%
Acquisitions
YoY Change
Other Investing Activities -$2.900M $790.0K $1.580M
YoY Change -160.92% -50.0% -74.64%
Cash From Investing Activities -$3.060M $680.0K $1.260M
YoY Change -167.25% -46.03% -79.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 460.0K 1.900M 550.0K
YoY Change 245.45% 816.67%
NET CHANGE
Cash From Operating Activities 4.980M -2.250M -6.340M
Cash From Investing Activities -3.060M 680.0K 1.260M
Cash From Financing Activities 460.0K 1.900M 550.0K
Net Change In Cash 2.380M 330.0K -4.530M
YoY Change -1352.63% -107.28% -2365.0%
FREE CASH FLOW
Cash From Operating Activities $4.980M -$2.250M -$6.340M
Capital Expenditures -$150.0K -$100.0K -$320.0K
Free Cash Flow $5.130M -$2.150M -$6.020M
YoY Change -213.25% -64.29% -0.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44812000 shares
CY2012Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56251350 shares
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6076000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
21102085
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.78
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2012Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
11700000 shares
CY2012Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2012Q3 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
8000
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
234000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5068823 shares
CY2012Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
14000
CY2012Q3 us-gaap Liabilities Current
LiabilitiesCurrent
16189000
CY2012Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1149000
CY2012Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7188000
CY2012Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-351651000
CY2012Q3 us-gaap Assets
Assets
86218000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6000.0
CY2012Q3 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
21000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
20964921
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8634000
CY2012Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
67373000
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
691000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.14
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5128827 shares
CY2012Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1059000
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
86218000
CY2012Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56216122 shares
CY2012Q3 us-gaap Common Stock Value
CommonStockValue
56000
CY2012Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
273000
CY2012Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2089451 shares
CY2012Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
57178000
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
641000
CY2012Q3 us-gaap Liabilities
Liabilities
130302000
CY2012Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
65825000
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
624000
CY2012Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1817000
CY2012Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
728000
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3007000
CY2012Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56216122 shares
CY2012Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
57191000
CY2012Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
46467000
CY2012Q3 us-gaap Assets Current
AssetsCurrent
84431000
CY2012Q3 us-gaap Other Receivables
OtherReceivables
17457000
CY2012Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
9400000
CY2012Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6445000
CY2012Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.12
CY2012Q3 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
57191000
CY2012Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
307497000
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
-44084000
CY2012Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11398737
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
663000
CY2012Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
739000
CY2012Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
154000
CY2012Q3 thld Plan Participants Withheld To Purchase Stock
PlanParticipantsWithheldToPurchaseStock
100000
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8691000
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2011Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
9209000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.45
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3672179 shares
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1349000
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22436000
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49128475 shares
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
49000
CY2011Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
153000
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2011Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
14409000
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2011Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
3000
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8591000
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
254000
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-252128000
CY2011Q4 us-gaap Assets
Assets
22436000
CY2011Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
2000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5882000
CY2011Q4 us-gaap Liabilities
Liabilities
17953000
CY2011Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
20258000
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1737000
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
543000
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49128475 shares
CY2011Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
14408000
CY2011Q4 us-gaap Assets Current
AssetsCurrent
20544000
CY2011Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4465000
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
14408000
CY2011Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
256563000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
4483000
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2389000
CY2012Q1 thld Aggregate Offering Price Of Common Stock
AggregateOfferingPriceOfCommonStock
15000000
thld Revenue Recognition Milestone Method Payment Received
RevenueRecognitionMilestoneMethodPaymentReceived
20000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14000.0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13730000
us-gaap Investment Income Interest
InvestmentIncomeInterest
20000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17646000
us-gaap Increase Decrease In Derivative Assets And Liabilities
IncreaseDecreaseInDerivativeAssetsAndLiabilities
1538000
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-10000
us-gaap Share Based Compensation
ShareBasedCompensation
743000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1538000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
395000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2615000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21936000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Net Income Loss
NetIncomeLoss
-20378000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4290000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44812000 shares
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30224000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
244000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20388000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-55000
us-gaap Operating Expenses
OperatingExpenses
21936000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
317000
us-gaap Share Based Goods And Nonemployee Services Transaction Expense
ShareBasedGoodsAndNonemployeeServicesTransactionExpense
51000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1022000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20378000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
26406000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
15000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
743000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
12993000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
798000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20378000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
53000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30224000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19109000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2012-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001183765
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Trading Symbol
TradingSymbol
THLD
dei Entity Registrant Name
EntityRegistrantName
THRESHOLD PHARMACEUTICALS INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y2M23D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
330352 shares
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12623000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53516000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M27D
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
53654000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-43619000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1400000
us-gaap Increase Decrease In Derivative Assets And Liabilities
IncreaseDecreaseInDerivativeAssetsAndLiabilities
-85572000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
15000
us-gaap Share Based Compensation
ShareBasedCompensation
2087000
us-gaap Investment Income Interest
InvestmentIncomeInterest
55000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.36
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1787000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.28
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-85572000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
668000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2752000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14006000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.86
us-gaap Net Income Loss
NetIncomeLoss
-99523000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
17457000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M27D
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.86
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5229000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53516000 shares
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21446000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-120000
us-gaap Contracts Revenue
ContractsRevenue
3846000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-99508000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
606000
us-gaap Operating Expenses
OperatingExpenses
17852000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
15000
thld Portion Of Profits In United States Depending On Total Sales
PortionOfProfitsInUnitedStatesDependingOnTotalSales
0.50 pure
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
328000
us-gaap Share Based Goods And Nonemployee Services Transaction Expense
ShareBasedGoodsAndNonemployeeServicesTransactionExpense
200000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1980000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-99523000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
75413000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2087000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
32122000
us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
3800000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
80000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-99523000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1650000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21446000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
24925000
thld Weighted Average Days To Maturity
WeightedAverageDaysToMaturity
157 D
thld Exercise Of Warrants Liability Measured At Fair Value
ExerciseOfWarrantsLiabilityMeasuredAtFairValue
27408000
thld Reclassifications Of Fair Value From Liability To Permanent Equity
ReclassificationsOfFairValueFromLiabilityToPermanentEquity
27400000
thld Reimbursement Expenses
ReimbursementExpenses
10000000
thld Worldwide Development Expenses Share Percentage
WorldwideDevelopmentExpensesSharePercentage
0.70 pure
CY2012Q1 thld Collaboration Agreement Upfront Payment
CollaborationAgreementUpfrontPayment
25000000
CY2011Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
CY2011Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6481000
CY2011Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49052000 shares
CY2011Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
3659000
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7789000
CY2011Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
-4125000
CY2011Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2011Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1308000
CY2011Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49052000 shares
CY2011Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4132000
CY2011Q3 us-gaap Operating Expenses
OperatingExpenses
7789000
CY2011Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7000
CY2011Q3 us-gaap Share Based Goods And Nonemployee Services Transaction Expense
ShareBasedGoodsAndNonemployeeServicesTransactionExpense
20000
CY2011Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4125000
CY2011Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
292000
CY2011Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4125000
CY2012Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
25000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4039000
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55654000 shares
CY2012Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1600000
CY2012Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
2967000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3983000
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-991000
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1741000
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64405000 shares
CY2012Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
8751000 shares
CY2012Q3 us-gaap Contracts Revenue
ContractsRevenue
1797000
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-964000
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
5780000
CY2012Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
27000
CY2012Q3 us-gaap Share Based Goods And Nonemployee Services Transaction Expense
ShareBasedGoodsAndNonemployeeServicesTransactionExpense
100000
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-991000
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
944000
CY2012Q3 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
1800000
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3958000
CY2012Q3 thld Reclassifications Of Fair Value From Liability To Permanent Equity
ReclassificationsOfFairValueFromLiabilityToPermanentEquity
5400000
CY2012Q3 thld Reimbursement Expenses
ReimbursementExpenses
5000000
CY2012Q3 thld Less Non Cash Income Change In Fair Value Of Warrants
LessNonCashIncomeChangeInFairValueOfWarrants
-2967000

Files In Submission

Name View Source Status
0001193125-12-449282-index-headers.html Edgar Link pending
0001193125-12-449282-index.html Edgar Link pending
0001193125-12-449282.txt Edgar Link pending
0001193125-12-449282-xbrl.zip Edgar Link pending
d413292d10q.htm Edgar Link pending
d413292dex311.htm Edgar Link pending
d413292dex312.htm Edgar Link pending
d413292dex321.htm Edgar Link pending
d413292dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
thld-20120930.xml Edgar Link completed
thld-20120930.xsd Edgar Link pending
thld-20120930_cal.xml Edgar Link unprocessable
thld-20120930_def.xml Edgar Link unprocessable
thld-20120930_lab.xml Edgar Link unprocessable
thld-20120930_pre.xml Edgar Link unprocessable